Literature DB >> 23321760

Mega-trials for blockbusters.

John P A Ioannidis1.   

Abstract

Mesh:

Year:  2013        PMID: 23321760     DOI: 10.1001/jama.2012.168095

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  12 in total

Review 1.  Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales.

Authors:  John P A Ioannidis; Fotini B Karassa; Eric Druyts; Kristian Thorlund; Edward J Mills
Journal:  Nat Rev Rheumatol       Date:  2013-09-03       Impact factor: 20.543

2.  Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

Authors:  Huseyin Naci; Olivier J Wouters; Radhika Gupta; John P A Ioannidis
Journal:  Milbank Q       Date:  2017-06       Impact factor: 4.911

3.  Counterpoint: were industry-sponsored roflumilast trials appropriate? No.

Authors:  Jason Rho; Nancy Ho; Vinay Prasad
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

4.  Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis.

Authors:  Nicholas S Downing; Theresa Cheng; Harlan M Krumholz; Nilay D Shah; Joseph S Ross
Journal:  JAMA Intern Med       Date:  2014-07       Impact factor: 21.873

5.  Another look at outcomes and outcome measures in psychiatry: cui bono?

Authors:  Cynthia L Arfken; Richard Balon
Journal:  Psychother Psychosom       Date:  2013-11-19       Impact factor: 17.659

6.  Are randomized trials obsolete or more important than ever in the genomic era?

Authors:  John Pa Ioannidis; Muin J Khoury
Journal:  Genome Med       Date:  2013-04-18       Impact factor: 11.117

7.  Evaluation in alcohol use disorders - insights from the nalmefene experience.

Authors:  Florian Naudet; Clément Palpacuer; Rémy Boussageon; Bruno Laviolle
Journal:  BMC Med       Date:  2016-08-18       Impact factor: 8.775

8.  Why Most Clinical Research Is Not Useful.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2016-06-21       Impact factor: 11.069

9.  Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey.

Authors:  Lars G Hemkens; Despina G Contopoulos-Ioannidis; John P A Ioannidis
Journal:  BMJ       Date:  2016-02-08

Review 10.  Routinely collected data for randomized trials: promises, barriers, and implications.

Authors:  Kimberly A Mc Cord; Rustam Al-Shahi Salman; Shaun Treweek; Heidi Gardner; Daniel Strech; William Whiteley; John P A Ioannidis; Lars G Hemkens
Journal:  Trials       Date:  2018-01-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.